查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1540887

2024-2032 年按產品類型、產品（Symplicity、Vessix、EnligHTN、Paradise、Iberis 等）、技術、應用、最終用戶和地區分類的腎去神經系統市場報告

Renal Denervation Systems Market Report by Product Type, Product (Symplicity, Vessix, EnligHTN, Paradise, Iberis, and Others), Technology, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球腎去神經系統市場規模達到4.438億美元。該市場是由高血壓盛行率上升、治療方法的技術進步以及證明療效的廣泛臨床試驗所推動的。醫院和診斷中心正在廣泛採用這些系統，再加上策略合作和監管部門的批准，進一步推動了市場的成長。

去腎神經系統市場分析：

主要市場促進因素：市場主要受到高血壓和抗藥性高血壓發病率上升的推動，這推動了對有效治療的需求。基於導管和非侵入性方法的技術進步提高了治療效率和安全性，從而促進了治療的採用。驗證長期效益的廣泛臨床試驗進一步促進了市場成長。人們越來越重視改善患者治療效果和管理慢性病，凸顯了去腎臟神經系統市場的成長。

主要市場趨勢：主要市場趨勢包括各種技術創新，例如先進的基於導管的系統和非侵入性系統，可提高整體功效和安全性。臨床試驗的逐漸增加正在驗證長期效益，進一步促進更廣泛的接受。批准正在加速市場進入，而策略合作則正在加強研發力度。高血壓發病率的上升也對去腎神經系統市場的成長做出了積極貢獻。

地理趨勢：市場的地理趨勢顯示歐洲的顯著採用和成長通常是由其先進的醫療基礎設施和有利的監管環境所推動的。北美地區也在逐漸擴張，這主要是由於高血壓盛行率的上升和各種技術的進步。由於醫療保健投資的增加和消費者意識的提高，亞太地區的市場活動顯著增加。拉丁美洲和中東是具有醫療保健系統成長潛力的新興市場。

競爭格局：去腎神經系統產業的一些主要市場參與者包括 Boston Scientific Group、Kona Medical Inc.、Medtronic Plc、Mercator MedSystems、ReCor Medical Inc.（Otsuka Holdings Co. Ltd.）、Renal Dynamics、St. Jude Medical Inc. (Abbott) 和Terumo Corporation 等。

挑戰與機會：市場面臨各種挑戰，如高成本、監管障礙和需要廣泛的臨床試驗。然而，它也帶來了機遇，例如技術進步、抗藥性高血壓增加導致的需求增加以及新興市場醫療保健基礎設施的擴大。策略合作和有利的監管發展進一步增強了成長潛力，同時人們對去腎神經支配益處的認知不斷提高，可以推動去腎神經支配系統市場在全球的成長和滲透。

去腎神經系統市場趨勢：

臨床試驗不斷增加

越來越多的臨床試驗對於腎臟去神經術市場至關重要，因為它們提供了有關該手術的長期益處和安全性的重要資料。這些試驗有助於確定腎去神經術在治療高血壓方面的功效，從而贏得醫療保健提供者和患者的信心。成功的試驗結果會獲得監管部門的批准，進一步推動產品的採用。此外，臨床試驗透過突出需要改進的領域和驗證新技術來促進創新，最終支持市場的成長和擴張。例如，2023 年 11 月，FDA 批准了一種超音波腎去神經裝置 Paradise 系統，用於治療對生活方式改變和藥物治療無反應的成人不受控制的高血壓。 ReCor Medical 的裝置使用超音波能量來去除腎動脈周圍的交感神經，從而減少與高血壓相關的過度活動。臨床研究表明血壓顯著降低，從而獲得了 FDA 的批准。這為努力控制血壓的患者帶來了新的希望。

高血壓盛行率上升

高血壓，特別是抗藥性高血壓盛行率的上升，大大推動了對腎臟去神經系統的需求。隨著全世界高血壓病例的增加，許多患者對傳統藥物沒有足夠的反應。根據世界衛生組織（WHO）發布的報告，全球估計有12.8億30-79歲的成年人患有高血壓，其中三分之二生活在低收入和中等收入國家。大約 46% 的成人高血壓患者不知道自己的病情，只有 42% 的人得到診斷和治療。大約 21% 的成年人的高血壓得到控制。高血壓是全球過早死亡的主要原因。這就迫切需要替代療法，例如腎去神經術，它透過針對腎臟神經來降低血壓提供了一個有前景的解決方案。隨著全球高血壓負擔的增加，採用有效、創新的治療方法（例如去腎神經術）的緊迫性不斷增強，從而促進了去腎神經系統市場的成長。

技術進步

腎臟去神經術的技術進步透過提高療效和安全性正在徹底改變治療方案。基於導管的技術創新正在提高精確度並降低手術風險，使腎去神經術更容易被更廣泛的患者群體所接受。非侵入性技術也越來越受到關注，提供了潛在的好處，例如縮短恢復時間和最小化患者不適。這些進步對於吸引更多的臨床採用至關重要，因為醫療保健提供者尋求可靠且有效的解決方案來管理高血壓和抗藥性高血壓，從而推動腎臟去神經術市場的成長。例如，2024 年 6 月，韓國醫療科技公司 DeepQure 啟動了一項早期可行性研究，以評估其腎臟去神經裝置 HyperQure 用於治療頑固性高血壓。這項研究涉及美國醫院的 15 名患者，先前 FDA 批准了研究設備豁免。該裝置能夠消融腎交感神經而不損傷血管內皮，使其在市場上脫穎而出。該公司的目標是繼這一監管里程碑之後推進全球臨床試驗。

去腎神經系統市場細分：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據產品類型、產品、技術、應用和最終用戶對市場進行了分類。

按產品類型分類：

導管

單電極導管

多電極導管

射頻發生器

神經調節劑

導管佔據大部分市場佔有率

該報告根據產品類型對市場進行了詳細的細分和分析。這包括導管（單電極導管、多電極導管）、射頻產生器和神經調節劑。根據該報告，導管佔最大部分。

導管在腎去神經系統市場佔有率中佔據主導地位，這主要是因為它們在直接向腎神經提供治療干預方面發揮著重要作用。這些設備可以針對交感神經進行微創手術，這對於調節血壓至關重要。先進的導管技術，包括基於射頻和超音波的系統，可在擾亂神經活動方面提供精確的控制和功效，同時確保患者的安全。基於導管的腎去神經術的越來越多的採用反映了它們在治療抗藥性高血壓和改善患者預後方面的有效性。例如，2024 年 3 月，FDA 批准了兩種新型微創導管式腎臟去神經裝置，用於幫助患有持續性高血壓的患者。這些設備針對交感神經來降低血壓，可能減少對某些抗高血壓藥物的需求。隨著創新不斷增強導管設計和手術技術，它們有望在不斷發展的高血壓治療領域中保持突出地位。

按產品分類：

簡單性

維斯克斯 (V2)

英利格HTN

天堂

伊貝里斯

其他

Symplicity 佔據業界最大佔有率

報告還提供了基於該產品的詳細市場細分和分析。這包括 Symplicity、Vessix (V2)、EnligHTN、Paradise、Iberis 等。報告顯示，Symplicity 佔據了最大的市場佔有率。

Symplicity 在腎去神經系統行業中佔有最大佔有率，這主要是因為它在開發基於導管的高血壓治療技術方面發揮了先鋒作用。 Symplicity 系統以其利用射頻能量破壞腎臟神經活動的功效而聞名，基於支持其有效性的臨床證據，已經建立了強大的市場地位。 2023 年 11 月，FDA 批准美敦力的 Symplicity 腎臟去神經系統用於治療高血壓。該系統採用基於導管的方法，透過射頻能量對腎動脈進行去神經支配。臨床試驗表明，接受該裝置的患者動態收縮壓顯著降低。該批准為結合藥物和生活方式改變的高血壓治療提供了一個有前途的替代方案。這一領先地位得到了持續的研究和開發工作的進一步鞏固，這些研究和開發工作旨在增強設備功能和擴大適應症，從而加強 Symplicity 在不斷發展的腎去神經療法領域的主導地位。

按技術分類：

超音波消融

射頻消融術

微量輸液

射頻消融術代表領先的細分市場

該報告基於該技術對市場進行了詳細的細分和分析。這包括超音波消融、射頻消融和微輸注。根據該報告，射頻消融佔據了最大的部分。

射頻消融確實是去腎神經系統市場的領先領域。該技術涉及使用射頻能量消融或停用腎神經，這有助於降低高血壓。與手術方法相比，它因其有效性和相對非侵入性而受到關注。射頻消融系統通常使用配備電極的導管將受控熱能傳遞到腎臟神經，從而破壞其功能。根據休士頓衛理公會發表的一篇文章，突破性的腎臟去神經術為慢性或難治性高血壓帶來了新的希望。這種微創手術利用射頻消融來破壞血壓升高的訊號，從而提供潛在的長期緩解。該細分市場的成長是由導管技術的進步、支持其功效的臨床證據的增加以及為改善治療抗藥性高血壓的手術結果和患者安全而進行的持續創新所推動的。

按應用分類：

高血壓

心臟疾病

糖尿病

腎衰竭

其他

報告還提供了基於應用程式的詳細市場細分和分析。這包括高血壓、心臟病、糖尿病、腎衰竭等。

腎臟去神經系統主要用於治療高血壓，特別是傳統藥物無效的頑固性高血壓。透過瞄準和破壞導致血壓升高的腎臟神經，這些系統為降低血壓提供了創新的解決方案。該應用程式因其提供非藥物治療選擇、改善患者預後並降低與不受控制的高血壓相關的心血管事件風險的潛力而受到廣泛關注。

在心臟病的情況下，腎臟去神經系統透過減少交感神經系統活動來幫助治療心臟衰竭和心房顫動等疾病。這種減少可以減輕心臟的壓力，改善心臟功能，並有可能預防心律不整。在心臟疾病中使用腎去神經術是一個新興領域，透過解決神經對這些疾病的影響並增強整體心血管健康，提供了有前景的益處。

去腎神經系統也正在探索其在治療糖尿病方面的潛在益處。透過調節交感神經系統，這些系統可以改善胰島素敏感性和葡萄糖代謝。該應用程式可以幫助儘管接受藥物治療但仍難以控制血糖的糖尿病患者，提供一種創新方法來管理糖尿病相關併發症並增強整體代謝健康。

對於腎衰竭患者，腎去神經系統旨在透過減少腎神經的過度活動來改善腎功能，腎神經的過度活動會加劇腎臟損傷。該應用的重點是減慢性腎臟疾病的進展並改善腎臟結果。透過針對導致腎功能障礙的潛在神經機制，這些系統為管理腎衰竭並可能改善受影響患者的生活品質提供了一種新的治療途徑。

按最終用戶分類：

診斷中心和醫院

門診護理中心

其他

診斷中心和醫院主導市場

該報告提供了基於最終用戶的詳細市場細分和分析。這包括診斷中心和醫院、門診護理中心等。根據該報告，診斷中心和醫院佔最大部分。

診斷中心和醫院憑藉其先進的醫療基礎設施和管理高血壓及相關疾病的專業知識，在腎臟去神經系統市場中佔據主導地位。這些機構配備了必要的技術和熟練的專業人員，可以安全有效地進行腎臟去神經術手術。此外，醫院和診斷中心提供的全面病患照護可確保徹底的術前評估和術後監測，從而提高病患的治療效果。它們在醫療保健服務中的核心作用使它們成為部署去腎神經技術、推動市場成長和這些創新治療方法採用的主要場所。

按地區分類：

北美洲

美國

加拿大

亞太地區

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

歐洲引領市場，佔據最大的去腎神經系統市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。根據報告，歐洲是去腎神經系統最大的區域市場。

由於先進的醫療基礎設施、廣泛的臨床研究和有利的監管環境，歐洲引領市場，佔據最大的去腎神經系統市場佔有率。該地區對創新醫療技術的重視和高血壓的高盛行率推動了腎去神經術的採用。德國、法國和英國等歐洲國家擁有健全的醫療保健系統，有助於先進治療的實施。根據IEA發布的報告，德國醫療保健市場至關重要，醫療技術市場每年價值約420億美元。醫療保健產業在德國經濟中發揮著舉足輕重的作用，佔德國 GDP 的 12%。德國醫療設備市場以歐元計算的複合年成長率預計為 5.1%，以美元計算為 6.8%，呈現成長機會。美國供應商有潛力參與醫療保健基礎設施和創新項目。此外，政府措施的大力支持和醫療保健研究投資的增加有助於歐洲在腎臟去神經術市場中佔據主導地位。

競爭格局：

市場研究報告也對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。去腎神經系統產業的一些主要市場參與者包括 Boston Scientific Group、Kona Medical Inc.、Medtronic Plc、Mercator MedSystems、ReCor Medical Inc.（Otsuka Holdings Co. Ltd.）、Renal Dynamics、St. Jude Medical Inc.。 （雅培）和泰爾茂公司。

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

腎臟去神經系統市場競爭激烈，美敦力 (Medtronic)、波士頓科學 (Boston Scientific) 和 ReCor Medical 等主要參與者在創新和市場佔有率方面處於領先地位。這些公司專注於技術進步、廣泛的臨床試驗和策略合作夥伴關係，以增強其產品組合和市場覆蓋範圍。例如，2024年5月，美敦力的Symplicity Spyral腎去神經術（RDN）系統獲得國家藥品監督管理局（NMPA）批准在中國商業化使用。該系統旨在解決高血壓這一中國的主要健康問題，並具有顯著降低血壓的潛力。繼最近 FDA 批准並在印度和加拿大推出後，這項批准增加了該設備在全球 70 多個國家的可用性。新興企業也以新穎的解決方案和微創技術進入市場，競爭壓力不斷增加。持續的研發工作和法規核准對於在這個快速發展的市場中保持競爭優勢發揮著至關重要的作用。

去腎神經系統市場新聞：

2024年6月，波士頓科學公司宣布以約11.6億美元收購Silk Road Medical, Inc.。 Silk Road Medical 的創新經頸動脈血管重建 (TCAR) 平台透過微創手術幫助頸動脈疾病患者預防中風。此次收購增強了波士頓科學公司的血管產品組合，並表明該公司致力於為周圍血管疾病提供先進的解決方案。該交易預計將於 2024 年下半年完成，具體取決於慣例成交條件。

2024 年 6 月，NexJ Health 和 Kona Medical Consulting 宣布結成策略聯盟，以轉變醫生群體基於價值的照護。透過將 NexJ 的虛擬健康計劃與 Kona 的管理服務組織專業知識相結合，該聯盟旨在加強患者護理、提高營運效率並滿足監管要求。此次合作開創了基於價值的護理的新時代，為全國的醫生團體提供了整合技術、專業知識和以患者為中心的整體解決方案。

本報告回答的關鍵問題：

  • 迄今為止，全球腎臟去神經系統市場表現如何，未來幾年將如何表現？
  • 全球去腎神經系統市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球去腎神經系統市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的腎去神經系統市場？
  • 依產品類型分類的市場是怎麼樣的？
  • 去腎神經系統市場中哪種產品類型最具吸引力？
  • 基於產品的市場區隔是什麼？
  • 去腎神經系統市場中哪一款產品最具吸引力？
  • 基於技術的市場區隔是什麼？
  • 去腎神經系統市場中哪一項技術最具吸引力？
  • 基於應用的市場區隔是什麼？
  • 腎臟去神經系統市場中最具吸引力的應用是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 去腎神經系統市場中哪個是最具吸引力的最終用戶？
  • 市場按地區分類是怎樣的？
  • 去腎神經系統市場哪個區域最具吸引力？
  • 市場競爭結構如何？
  • 全球去腎神經系統市場的主要參與者/公司有哪些？

本報告回答的關鍵問題：

  • 迄今為止，全球腎臟去神經系統市場表現如何，未來幾年將如何表現？
  • 全球去腎神經系統市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球去腎神經系統市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的腎去神經系統市場？
  • 依產品類型分類的市場是怎麼樣的？
  • 去腎神經系統市場中哪種產品類型最具吸引力？
  • 基於產品的市場區隔是什麼？
  • 去腎神經系統市場中哪種產品最具吸引力？
  • 基於技術的市場區隔是什麼？
  • 去腎神經系統市場中哪一項技術最具吸引力？
  • 基於應用的市場區隔是什麼？
  • 去腎神經系統市場哪一個應用最吸引人？
  • 基於最終用戶的市場區隔是什麼？
  • 去腎神經系統市場中哪個是最具吸引力的最終用戶？
  • 市場按地區分類是怎樣的？
  • 去腎神經系統市場哪個區域最具吸引力？
  • 市場競爭結構如何？
  • 全球去腎神經系統市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球去腎神經系統市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品類型

  • 導管
    • 市場趨勢
    • 主要類型
      • 單電極導管
      • 多電極導管
    • 市場預測
  • 射頻發生器
    • 市場趨勢
    • 市場預測
  • 神經調節劑
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依產品

  • 簡單性
    • 市場趨勢
    • 市場預測
  • 維斯克斯 (V2)
    • 市場趨勢
    • 市場預測
  • 英利格HTN
    • 市場趨勢
    • 市場預測
  • 天堂
    • 市場趨勢
    • 市場預測
  • 伊貝里斯
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依技術

  • 超音波消融
    • 市場趨勢
    • 市場預測
  • 射頻消融術
    • 市場趨勢
    • 市場預測
  • 微量輸液
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按應用

  • 高血壓
    • 市場趨勢
    • 市場預測
  • 心臟疾病
    • 市場趨勢
    • 市場預測
  • 糖尿病
    • 市場趨勢
    • 市場預測
  • 腎衰竭
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：依最終用戶

  • 診斷中心和醫院
    • 市場趨勢
    • 市場預測
  • 門診護理中心
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 11 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 12 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 13 章：價值鏈分析

第 14 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 15 章：價格分析

第16章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Boston Scientific Group
    • Kona Medical Inc.
    • Medtronic Plc
    • Mercator MedSystems
    • ReCor Medical Inc. (Otsuka Holdings Co. Ltd.)
    • Renal Dynamics
    • St. Jude Medical Inc. (Abbott)
    • Terumo Corporation
Product Code: SR112024A2558

The global renal denervation systems market size reached US$ 443.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 6,077.3 Million by 2032, exhibiting a growth rate (CAGR) of 32.7% during 2024-2032. The market is driven by the rising prevalence of hypertension, technological advancements in treatment methods, and extensive clinical trials demonstrating efficacy. Hospitals and diagnostic centers are widely adopting these systems, which, along with strategic collaborations and regulatory approvals are further fuelingl market growth.

Renal Denervation Systems Market Analysis:

Major Market Drivers: The market is mainly driven by the rising incidence of hypertension and drug resistant hypertension which drives the demand for effective treatments. Technological advancements in catheter based and non-invasive methods enhances the treatment efficiency and safety thereby fostering the adoption. Extensive clinical trials validating long term benefits further boost the market growth. The growing emphasis on improving patient outcomes and managing chronic conditions underscores the renal denervation systems market growth.

Key Market Trends: Key market trends include various technological innovations like advanced catheter-based systems and non-invasive systems which improves the overall efficacy and safety. Gradual increase in clinical trials is validating long term benefits further fostering the wider acceptance. Approvals are accelerating the market entry while strategic collaborations are enhancing the research and development efforts. The rising incidence of hypertension is also contributing positively to the renal denervation systems market growth.

Geographical Trends: Geographical trends in the market shows significant adoption and growth in Europe generally driven by their advanced healthcare infrastructure and favorable regulatory environments. North America is also expanding gradually mainly due to the rising prevalence of hypertension and various technological advancements. The Asia Pacific is witnessing a significant increase in market activity due to the growing healthcare investments and rising awareness among consumers. Latin America and Middle East are emerging markets with potential for growth as healthcare systems.

Competitive Landscape: Some of the major market players in the renal denervation systems industry include Boston Scientific Group, Kona Medical Inc., Medtronic Plc, Mercator MedSystems, ReCor Medical Inc. (Otsuka Holdings Co. Ltd.), Renal Dynamics, St. Jude Medical Inc. (Abbott) and Terumo Corporation, among many others.

Challenges and Opportunities: The market faces various challenges like high costs, regulatory hurdles and the need for extensive clinical trials. However, it also presents opportunities such as technological advancements, increasing demand due to the rise in drug-resistant hypertension, and expanding healthcare infrastructure in emerging markets. Strategic collaborations and favorable regulatory developments further enhance growth potential, while rising awareness about renal denervation benefits can drive the renal denervation systems market growth and penetration globally.

Renal Denervation Systems Market Trends:

Rising Clinical Trials

Increasing clinical trials are pivotal for the renal denervation market as they provide essential data on the long-term benefits and safety of the procedure. These trials help establish the efficacy of renal denervation in managing hypertension, thereby gaining confidence among healthcare providers and patients. Successful trial outcomes lead to regulatory approvals, thereby further driving the product adoption. Additionally, clinical trials foster innovation by highlighting areas for improvement and validating new technologies, ultimately supporting market growth and expansion. For instance, in November 2023, FDA approved an ultrasound renal denervation device, the Paradise system, for treating uncontrolled hypertension in adults not responding to lifestyle changes and medications. The device by ReCor Medical uses ultrasound energy to denervate sympathetic nerves surrounding the renal arteries reducing hypertension-related overactivity. Clinical studies demonstrated a significant reduction in blood pressure leading to the FDA's approval. This offers new hope for patients struggling to control their blood pressure.

Rising Prevalence of Hypertension

The rising prevalence of hypertension, particularly drug-resistant hypertension, is significantly driving the demand for renal denervation systems. With increasing cases of hypertension worldwide, many patients do not respond adequately to traditional medications. According to the report published by the World Health Organization (WHO), an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension with two-thirds living in low- and middle-income countries. Approximately 46% of adults with hypertension are unaware of their condition and only 42% are diagnosed and treated. Around 21% of adults have their hypertension under control. Hypertension is a major cause of premature death globally. This creates a pressing need for alternative treatments like renal denervation, which offers a promising solution by targeting the renal nerves to lower blood pressure. As the global burden of hypertension grows, the urgency to adopt effective, innovative treatments such as renal denervation continues to intensify, boosting renal denervation systems market growth.

Technological Advancements

Technological advancements in renal denervation are revolutionizing treatment options by enhancing both efficacy and safety profiles. Innovations in catheter-based techniques are improving precision and reducing procedural risks, making renal denervation more accessible to a broader patient base. Non-invasive technologies are also gaining traction, offering potential benefits such as reduced recovery times and minimal patient discomfort. These advancements are crucial in attracting greater clinical adoption as healthcare providers seek reliable and efficient solutions for managing hypertension and drug-resistant hypertension, thereby driving growth in the renal denervation market. For instance, in June 2024, South Korean medtech firm DeepQure initiated an Early Feasibility Study to assess its renal denervation device, HyperQure, for treating resistant hypertension. The study, involving 15 patients across US hospitals, follows FDA approval for investigational device exemption. The device's ability to ablate renal sympathetic nerves without damaging the vascular endothelium distinguishes it in the market. The company aims to advance global clinical trials following this regulatory milestone.

Renal Denervation Systems Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, product, technology, application and end user.

Breakup by Product Type:

Catheters

Single Electrode Catheter

Multi Electrode Catheter

RF Generator

Nerve Modifying Agents

Catheters accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes catheters (single electrode catheter, multi electrode catheter), RF generator and nerve modifying agents. According to the report, catheters represented the largest segment.

Catheters dominate the renal denervation systems market share, primarily due to their essential role in delivering therapeutic interventions directly to renal nerves. These devices enable minimally invasive procedures that target sympathetic nerves, crucial for regulating blood pressure. Advanced catheter technologies, including radiofrequency and ultrasound-based systems, offer precise control and efficacy in disrupting nerve activity while ensuring patient safety. The increasing adoption of catheter-based renal denervation reflects their effectiveness in treating drug-resistant hypertension and improving patient outcomes. For instance, in March 2024, two new minimally invasive catheter-based renal denervation devices have been approved by the FDA to help people with persistent hypertension. These devices target sympathetic nerves to lower blood pressure, potentially reducing the need for some antihypertensive medications. As innovations continue to enhance catheter designs and procedural techniques, they are expected to maintain their prominent position in the evolving landscape of hypertension management.

Breakup by Product:

Symplicity

Vessix (V2)

EnligHTN

Paradise

Iberis

Others

Symplicity holds the largest share of the industry

A detailed breakup and analysis of the market based on the product have also been provided in the report. This includes Symplicity, Vessix (V2), EnligHTN, Paradise, Iberis and others. According to the report, Symplicity accounted for the largest market share.

Symplicity holds the largest share of the renal denervation systems industry primarily due to its pioneering role in developing catheter-based technologies for treating hypertension. The Symplicity system, known for its efficacy in disrupting renal nerve activity using radiofrequency energy, has established a strong market presence based on clinical evidence supporting its effectiveness. In November 2023, FDA approves Medtronic's Symplicity Renal Denervation System to treat hypertension. The system uses a catheter-based approach to denervate the renal arteries with radiofrequency energy. Clinical trials showed a significant reduction in ambulatory systolic blood pressure in patients who received the device. The approval offers a promising alternative for hypertension treatment in combination with medication and lifestyle changes. This leadership position is further bolstered by ongoing research and development efforts aimed at enhancing device capabilities and expanding indications, reinforcing Symplicity's dominance in the evolving landscape of renal denervation therapies.

Breakup by Technology:

Ultrasound Ablation

Radiofrequency Ablation

Microinfusion

Radiofrequency Ablation represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the technology. This includes ultrasound ablation, radiofrequency ablation and microinfusion. According to the report, radiofrequency ablation represented the largest segment.

Radiofrequency ablation is indeed a leading segment in the renal denervation systems market. This technology involves using radiofrequency energy to ablate or deactivate renal nerves, which helps in reducing hypertension. It has gained prominence due to its effectiveness and relative non-invasiveness compared to surgical approaches. Radiofrequency ablation systems typically use catheters equipped with electrodes to deliver controlled thermal energy to the renal nerves, thereby disrupting their function. According to an article published by Houston Methodist, a groundbreaking renal denervation procedure offers new hope for chronic or treatment-resistant hypertension. The minimally invasive procedure disrupts blood pressure-elevating signals using radiofrequency ablation, providing potential long-term relief. This segment's growth is driven by advancements in catheter technology, increasing clinical evidence supporting its efficacy, and ongoing innovations to improve procedural outcomes and patient safety in treating drug-resistant hypertension.

Breakup by Application:

Hypertension

Cardiac Disorders

Diabetes

Renal Failure

Others

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes hypertension, cardiac disorders, diabetes, renal failure and others.

Renal denervation systems are primarily used to treat hypertension, especially resistant hypertension where traditional medications are ineffective. By targeting and disrupting renal nerves that contribute to elevated blood pressure, these systems provide an innovative solution for lowering blood pressure. This application has gained significant attention due to its potential to offer a non-pharmacological treatment option, improving patient outcomes and reducing the risk of cardiovascular events associated with uncontrolled hypertension.

In the context of cardiac disorders, renal denervation systems help manage conditions like heart failure and atrial fibrillation by reducing sympathetic nervous system activity. This reduction can alleviate stress on the heart, improve cardiac function, and potentially prevent arrhythmias. The use of renal denervation in cardiac disorders is an emerging field, offering promising benefits by addressing the neural contributions to these conditions and enhancing overall cardiovascular health.

Renal denervation systems are also being explored for their potential benefits in managing diabetes. By modulating the sympathetic nervous system, these systems may improve insulin sensitivity and glucose metabolism. This application could help diabetic patients who struggle with blood sugar control despite medication, offering an innovative approach to managing diabetes-related complications and enhancing overall metabolic health.

For patients with renal failure, renal denervation systems aim to improve kidney function by reducing the overactivity of renal nerves that can exacerbate kidney damage. This application focuses on slowing the progression of chronic kidney disease and improving renal outcomes. By targeting the underlying neural mechanisms contributing to renal dysfunction, these systems offer a novel therapeutic avenue for managing renal failure and potentially improving quality of life for affected patients.

Breakup by End User:

Diagnostic Centers and Hospitals

Ambulatory Care Centers

Others

Diagnostic Centers and Hospitals dominate the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes diagnostic centers and hospitals, ambulatory care centers and others. According to the report, diagnostic centers and hospitals represented the largest segment.

Diagnostic centers and hospitals dominate the renal denervation systems market due to their advanced medical infrastructure and expertise in managing hypertension and related conditions. These institutions are equipped with the necessary technology and skilled professionals to perform renal denervation procedures safely and effectively. Additionally, the comprehensive patient care provided by hospitals and diagnostic centers ensures thorough pre-procedure assessments and post-procedure monitoring, enhancing patient outcomes. Their central role in healthcare delivery makes them the primary settings for deploying renal denervation technologies, driving market growth and adoption of these innovative treatments.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Europe leads the market, accounting for the largest renal denervation systems market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe represents the largest regional market for renal denervation systems.

Europe leads the market, holding the largest renal denervation systems market share due to advanced healthcare infrastructure, extensive clinical research, and favorable regulatory environments. The region's emphasis on innovative medical technologies and high prevalence of hypertension drives the adoption of renal denervation procedures. European countries like Germany, France, and the UK have robust healthcare systems that facilitate the implementation of advanced treatments. According to the report published by IEA, the German healthcare market is crucial, with a medical technology market valued at approximately $42 billion annually. The healthcare sector plays a pivotal role in the country's economy, representing 12% of Germany's GDP. With an expected CAGR of 5.1% in Euro-terms and 6.8% in USD-terms, the German medical equipment market presents opportunities for growth. U.S. suppliers have potential to engage in healthcare infrastructure and innovation projects. Moreover, strong support from government initiatives and increased investment in healthcare research contribute to Europe's dominant position in the renal denervation market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the renal denervation systems industry include Boston Scientific Group, Kona Medical Inc., Medtronic Plc, Mercator MedSystems, ReCor Medical Inc. (Otsuka Holdings Co. Ltd.), Renal Dynamics, St. Jude Medical Inc. (Abbott) and Terumo Corporation.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The Renal Denervation Systems market is highly competitive, with key players such as Medtronic, Boston Scientific, and ReCor Medical leading innovation and market share. These companies focus on technological advancements, extensive clinical trials, and strategic partnerships to enhance their product portfolios and market reach. For instance, in May 2024, Medtronic's Symplicity Spyral renal denervation (RDN) system was approved for commercial use in China by the National Medical Products Administration (NMPA). The system aims to address hypertension, a major health concern in China, with the potential for significant blood pressure reduction. This approval adds to the device's availability in over 70 countries globally, following recent FDA approval and launch in India and Canada. Emerging players are also entering the market with novel solutions and minimally invasive technologies, increasing competitive pressure. Continuous R&D efforts and regulatory approvals play crucial roles in maintaining a competitive edge in this rapidly evolving market.

Renal Denervation Systems Market News:

In June 2024, Boston Scientific announced the acquisition of Silk Road Medical, Inc. for approximately $1.16 billion. Silk Road Medical's innovative transcarotid artery revascularization (TCAR) platform helps prevent strokes in patients with carotid artery disease through a minimally invasive procedure. The acquisition enhances Boston Scientific's vascular portfolio and demonstrates the company's dedication to providing advanced solutions for peripheral vascular disease. The transaction is expected to be completed in the second half of 2024, subject to customary closing conditions.

In June 2024, NexJ Health and Kona Medical Consulting announced a strategic alliance to transform value-based care for physician groups. By combining NexJ's virtual health programs with Kona's managed service organization expertise, the alliance aims to enhance patient care, improve operational efficiency, and address regulatory requirements. This collaboration introduces a new era in value-based care, offering a holistic solution that integrates technology, expertise, and patient-centricity for physician groups nationwide.

Key Questions Answered in This Report:

  • How has the global renal denervation systems market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global renal denervation systems market?
  • What is the impact of each driver, restraint, and opportunity on the global renal denervation systems market?
  • What are the key regional markets?
  • Which countries represent the most attractive renal denervation systems market?
  • What is the breakup of the market based on the product type?
  • Which is the most attractive product type in the renal denervation systems market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the renal denervation systems market?
  • What is the breakup of the market based on the technology?
  • Which is the most attractive technology in the renal denervation systems market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the renal denervation systems market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the renal denervation systems market?
  • What is the breakup of the market based on the region?
  • Which is the most attractive region in the renal denervation systems market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global renal denervation systems market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Renal Denervation Systems Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Catheters
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Single Electrode Catheter
      • 6.1.2.2 Multi Electrode Catheter
    • 6.1.3 Market Forecast
  • 6.2 RF Generator
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Nerve Modifying Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Symplicity
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Vessix (V2)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 EnligHTN
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Paradise
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Iberis
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Ultrasound Ablation
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Radiofrequency Ablation
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Microinfusion
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Hypertension
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Cardiac Disorders
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Diabetes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Renal Failure
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Diagnostic Centers and Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Ambulatory Care Centers
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Boston Scientific Group
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Kona Medical Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Medtronic Plc
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Mercator MedSystems
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
    • 16.3.5 ReCor Medical Inc. (Otsuka Holdings Co. Ltd.)
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Renal Dynamics
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
    • 16.3.7 St. Jude Medical Inc. (Abbott)
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Terumo Corporation
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Renal Denervation Systems Market: Major Drivers and Challenges
  • Figure 2: Global: Renal Denervation Systems Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Renal Denervation Systems Market: Breakup by Product Type (in %), 2023
  • Figure 4: Global: Renal Denervation Systems Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Renal Denervation Systems Market: Breakup by Technology (in %), 2023
  • Figure 6: Global: Renal Denervation Systems Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Renal Denervation Systems Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Renal Denervation Systems Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Renal Denervation Systems (Catheters) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Renal Denervation Systems (Catheters) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Renal Denervation Systems (RF Generator) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Renal Denervation Systems (RF Generator) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Renal Denervation Systems (Nerve Modifying Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Renal Denervation Systems (Nerve Modifying Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Renal Denervation Systems (Symplicity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Renal Denervation Systems (Symplicity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Renal Denervation Systems (Vessix- V2) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Renal Denervation Systems (Vessix- V2) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Renal Denervation Systems (EnligHTN) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Renal Denervation Systems (EnligHTN) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Renal Denervation Systems (Paradise) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Renal Denervation Systems (Paradise) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Renal Denervation Systems (Iberis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Renal Denervation Systems (Iberis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Renal Denervation Systems (Other Product Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Renal Denervation Systems (Other Product Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Renal Denervation Systems (Ultrasound Ablation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Renal Denervation Systems (Ultrasound Ablation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Renal Denervation Systems (Radiofrequency Ablation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Renal Denervation Systems (Radiofrequency Ablation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Renal Denervation Systems (Microinfusion) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Renal Denervation Systems (Microinfusion) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Renal Denervation Systems (Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Renal Denervation Systems (Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Renal Denervation Systems (Cardiac Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Renal Denervation Systems (Cardiac Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Renal Denervation Systems (Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Renal Denervation Systems (Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Renal Denervation Systems (Renal Failure) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Renal Denervation Systems (Renal Failure) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Renal Denervation Systems (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Renal Denervation Systems (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Global: Renal Denervation Systems (Diagnostic Centers and Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Global: Renal Denervation Systems (Diagnostic Centers and Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Global: Renal Denervation Systems (Ambulatory Care Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Renal Denervation Systems (Ambulatory Care Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Renal Denervation Systems (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Renal Denervation Systems (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: North America: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: North America: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United States: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United States: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Canada: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Canada: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Asia Pacific: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Asia Pacific: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: China: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: China: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Japan: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Japan: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: India: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: India: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: South Korea: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: South Korea: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Australia: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Australia: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Indonesia: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Indonesia: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Europe: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Europe: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Germany: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Germany: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: France: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: France: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: United Kingdom: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: United Kingdom: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Italy: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Italy: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Spain: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Spain: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Russia: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Russia: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Others: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Others: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Latin America: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Latin America: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Brazil: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Brazil: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Mexico: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Mexico: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Others: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Others: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Middle East and Africa: Renal Denervation Systems Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Middle East and Africa: Renal Denervation Systems Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 98: Global: Renal Denervation Systems Industry: SWOT Analysis
  • Figure 99: Global: Renal Denervation Systems Industry: Value Chain Analysis
  • Figure 100: Global: Renal Denervation Systems Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Renal Denervation Systems Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Renal Denervation Systems Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Renal Denervation Systems Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Renal Denervation Systems Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 5: Global: Renal Denervation Systems Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Renal Denervation Systems Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 7: Global: Renal Denervation Systems Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Renal Denervation Systems Market Structure
  • Table 9: Global: Renal Denervation Systems Market: Key Players